Zecheng Chen

发表

Synthesis of 3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol, a potent antineoplastic benzosuberene derivative for anti-cancer chemotherapy

C. J. O’Donnell, A. Maderna, Zecheng Chen, 2012 .

A 12-hour rapid titration method for cancer pain: a randomized, controlled, open-label study.

W. Feng, Yan-ming Deng, Zecheng Chen, 2021, Annals of palliative medicine.

Application of Quantitative NMR in Pharmacological Evaluation of Biologically Generated Metabolites: Implications in Drug Discovery

R. Talaat, A. Mutlib, J. Scatina, 2011, Drug Metabolism and Disposition.

Abstract 723: Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor

R. Abraham, N. Brooijmans, L. Feldberg, 2010 .

The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer.

Jing Wu, W. Feng, Yan-ming Deng, 2014, Molecular and clinical oncology.

Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.

N. Brooijmans, L. Feldberg, R. Mallon, 2010, Journal of medicinal chemistry.

Total synthesis of (+/-)-alantrypinone by hetero Diels-Alder reaction.

A. Kende, Zecheng Chen, Junfa Fan, 2004, The Journal of organic chemistry.

A concise total synthesis of (+/-)-alantrypinone by a novel hetero-Diels-Alder reaction.

A. Kende, Zecheng Chen, Junfa Fan, 2003, Organic letters.

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

R. Abraham, N. Brooijmans, L. Feldberg, 2010, Journal of medicinal chemistry.

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

L. Feldberg, R. Mallon, J. Lucas, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical Antitumor Efficacy of PKI-587 , a Highly Potent Dual PI 3 K / mTOR Kinase Inhibitor

L. Feldberg, R. Mallon, J. Lucas, 2011 .

PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.

L. Feldberg, R. Mallon, J. Lucas, 2010, Bioorganic & medicinal chemistry letters.

Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor

L. Feldberg, R. Mallon, J. Gibbons, 2010, Molecular Cancer Therapeutics.

Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.

N. Brooijmans, L. Feldberg, R. Mallon, 2011, Bioorganic & medicinal chemistry letters.

Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.

R. Abraham, N. Brooijmans, L. Feldberg, 2010, Bioorganic & medicinal chemistry letters.

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.

Judy Lucas, Irwin Hollander, Robert Mallon, 2010, Journal of medicinal chemistry.

Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition.

M. Follettie, N. Brooijmans, J. Lucas, 2010, Journal of medicinal chemistry.

2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer.

J. Lucas, T. Mansour, K. Arndt, 2009, Bioorganic & medicinal chemistry letters.

Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study

W. Feng, Yan-ming Deng, Zecheng Chen, 2020, Therapeutic advances in medical oncology.

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

Sai Chetan K. Sukuru, Frank Loganzo, Michael J. Shapiro, 2015 .

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.

Frank Loganzo, Carolyn A Leverett, Chakrapani Subramanyam, 2014, Journal of medicinal chemistry.

Mechanism of an unusual decarboxylative cyclization

A. Kende, Zecheng Chen, O. Henry, 2004 .

Stereoselective synthesis of an active metabolite of the potent PI3 kinase inhibitor PKI-179.

T. Mansour, S. Ayral-Kaloustian, L. McDonald, 2010, The Journal of organic chemistry.

Polarization-Resolved p-Se/n-WS2 Heterojunctions toward Application in Microcomputer System as Multivalued Signal Trigger.

Wei Gao, Xueting Liu, Ling Li, 2022, Small.

Bi2O2Se Nanowire/MoSe2 Mixed-Dimensional Polarization-Sensitive Photodiode with a Nanoscale Ultrafast-Response Channel.

Wei Gao, Nengjie Huo, Jingbo Li, 2023, ACS applied materials & interfaces.

IL-37 mediates the anti-tumor activity in non-small cell lung cancer through IL-6/STAT3 pathway

W. Feng, Yan-ming Deng, Zecheng Chen, 2018 .

Application of Quantitative NMR in Pharmacological Evaluation of Biologically Generated Metabolites: Implications in Drug Discovery

R. Talaat, A. Mutlib, J. Scatina, 2011, Drug Metabolism and Disposition.

R. Abraham, N. Brooijmans, R. Mallon, 2010, Journal of medicinal chemistry.

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

R. Abraham, N. Brooijmans, R. Mallon, 2010, Journal of medicinal chemistry.

Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.

R. Abraham, N. Brooijmans, R. Mallon, 2010, Bioorganic & medicinal chemistry letters.

Nonlinear dynamic analysis and structural optimization design of Ni/Mg modified single wall carbon nanotube for hydrogen storage

Zecheng Chen, Mingliang Liu, J. Xu, 2022, International Journal of Hydrogen Energy.